drugset / Trial / NCT04681105
Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies
NaSingle-groupOpen-labelTreatment
Summary
This phase I trial studies the best dose and side effects of flotetuzumab for the treatment of patients with blood cancers (hematological malignancies) that have spread to other places in the body (advanced) and have come back after a period of improvement (relapsed) or does not respond to treatment (refractory). Flotetuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread.
Timeline
- Start
- 2020-11-18
- Primary completion
- 2025-08-05
- Completion
- 2025-08-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Flotetuzumab | Monoclonal antibody | — | Intravenous |
| Background | Acetaminophen | Small molecule | — | Oral |
| Background | Dexamethasone | Small molecule | — | Intravenous |
| Background | Diphenhydramine | Unknown | — | Intravenous |
| Background | Ibuprofen | Small molecule | — | Oral |
| Background | Ranitidine | Unknown | — | Intravenous |